These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 28343164)

  • 1. A Quantitative Concordance Measure for Comparing and Combining Treatment Selection Markers.
    Zhang Z; Ma S; Nie L; Soon G
    Int J Biostat; 2017 Mar; 13(1):. PubMed ID: 28343164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of auxiliary covariates in estimating a biomarker-adjusted treatment effect model with clinical trial data.
    Zhang Z; Qu Y; Zhang B; Nie L; Soon G
    Stat Methods Med Res; 2016 Oct; 25(5):2103-2119. PubMed ID: 24346166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying predictive markers for personalized treatment selection.
    Shen Y; Cai T
    Biometrics; 2016 Dec; 72(4):1017-1025. PubMed ID: 26999054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining biomarkers for classification with covariate adjustment.
    Kim S; Huang Y
    Stat Med; 2017 Jul; 36(15):2347-2362. PubMed ID: 28276080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of approaches for combining predictive markers for personalised treatment recommendations.
    Pierce M; Emsley R
    Trials; 2021 Jan; 22(1):20. PubMed ID: 33407760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Auxiliary variable-enriched biomarker-stratified design.
    Wang T; Wang X; Zhou H; Cai J; George SL
    Stat Med; 2018 Dec; 37(30):4610-4635. PubMed ID: 30221368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relative efficiency of precision medicine designs for clinical trials with predictive biomarkers.
    Shih WJ; Lin Y
    Stat Med; 2018 Feb; 37(5):687-709. PubMed ID: 29205435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incorporating covariates information in adaptive clinical trials for precision medicine.
    Zhao W; Ma W; Wang F; Hu F
    Pharm Stat; 2022 Jan; 21(1):176-195. PubMed ID: 34369053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantiles based personalized treatment selection for multivariate outcomes and multiple treatments.
    Kulasekera KB; Siriwardhana C
    Stat Med; 2022 Jul; 41(15):2695-2710. PubMed ID: 35699385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical study designs and patient selection methods based on genomic biomarkers: Points-to-consider documents.
    Tohkin M; Saito Y; Yagi S; Asano K; Maekawa K; Osabe M; Iida S; Miyata N
    Drug Metab Pharmacokinet; 2020 Apr; 35(2):187-190. PubMed ID: 32007355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal two-stage enrichment design correcting for biomarker misclassification.
    Zang Y; Guo B
    Stat Methods Med Res; 2018 Jan; 27(1):35-47. PubMed ID: 26614756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Biomarkers on Personalized Medicine.
    Carrigan P; Krahn T
    Handb Exp Pharmacol; 2016; 232():285-311. PubMed ID: 26330258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating marker-guided treatment selection strategies.
    Matsouaka RA; Li J; Cai T
    Biometrics; 2014 Sep; 70(3):489-499. PubMed ID: 24779731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating markers for treatment selection based on survival time.
    Song X; Zhou XH
    Stat Med; 2011 Aug; 30(18):2251-64. PubMed ID: 21611957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simple subgroup approximations to optimal treatment regimes from randomized clinical trial data.
    Foster JC; Taylor JM; Kaciroti N; Nan B
    Biostatistics; 2015 Apr; 16(2):368-82. PubMed ID: 25398774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimation of treatment effect in two-stage confirmatory oncology trials of personalized medicines.
    Li W; Chen C; Li X; Beckman RA
    Stat Med; 2017 May; 36(12):1843-1861. PubMed ID: 28303586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of predictive signatures for treatment selection in precision medicine with survival outcomes.
    Chen YC; Lee UJ; Tsai CA; Chen JJ
    Pharm Stat; 2018 Mar; 17(2):105-116. PubMed ID: 29297979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Personalized Cardiovascular Medicine Today: A Food and Drug Administration/Center for Drug Evaluation and Research Perspective.
    Blaus A; Madabushi R; Pacanowski M; Rose M; Schuck RN; Stockbridge N; Temple R; Unger EF
    Circulation; 2015 Oct; 132(15):1425-32. PubMed ID: 26459078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Translating predictive biomarkers within oncology clinical development programs.
    Beckman RA; Chen C
    Biomark Med; 2015; 9(9):851-62. PubMed ID: 26330133
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.